Treosulfan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Treosulfan
Accession Number
DB11678
Type
Small Molecule
Groups
Investigational
Description

Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood.

Structure
Thumb
Synonyms
  • DIHYDROXYBUSULFAN
  • OVASTAT
External IDs
NSC-39069
Categories
UNII
CO61ER3EPI
CAS number
299-75-2
Weight
Average: 278.29
Monoisotopic: 278.013009759
Chemical Formula
C6H14O8S2
InChI Key
YCPOZVAOBBQLRI-WDSKDSINSA-N
InChI
InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3/t5-,6-/m0/s1
IUPAC Name
(2S,3S)-2,3-dihydroxy-4-(methanesulfonyloxy)butyl methanesulfonate
SMILES
CS(=O)(=O)OC[[email protected]](O)[[email protected]@H](O)COS(C)(=O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Treosulfan.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Treosulfan.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Treosulfan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Treosulfan.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Treosulfan.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Treosulfan.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Treosulfan.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Treosulfan.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Treosulfan.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Treosulfan.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Treosulfan.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Treosulfan.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Treosulfan.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Treosulfan.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Treosulfan.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Treosulfan.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Treosulfan.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Treosulfan.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Treosulfan.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C19557
PubChem Compound
9882105
PubChem Substance
347828046
ChemSpider
8057780
ChEBI
82557
ChEMBL
CHEMBL455186
ATC Codes
L01AB02 — Treosulfan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentHaematological Malignancies1
1, 2CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
1, 2Unknown StatusTreatmentMultiple Myeloma (MM)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Juvenile Myelomonocytic Leukaemias (JMML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
2Active Not RecruitingTreatmentAcute myeloid leukaemia (in remission) / Chronic Myelomonocytic Leukemia / Minimal Residual Disease / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myelodysplastic/Myeloproliferative Neoplasms1
2Active Not RecruitingTreatmentLymphoma, Hodgkins / Non Hodgkin Lymphoma (NHL)1
2CompletedSupportive CareLeukemia Acute Myeloid Leukemia (AML)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
2CompletedTreatmentMyelodysplastic Syndrome1
2CompletedTreatmentProstate Cancer1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Myelodysplastic Syndrome / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Myelodysplastic Syndrome / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Myelodysplastic Syndrome With Excess Blasts-2 / RAEB-2 / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Anemia With Excess Blasts / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive1
2RecruitingTreatmentBone Marrow Failure Syndromes / Congenital Immunodeficiency / Haemoglobinopathies congenital / Inborn Errors of Metabolism1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-squamous Cell Lung Cancer / Squamous Cell Carcinoma of Lung1
2RecruitingTreatmentNon-Malignant1
2Unknown StatusPreventionGraft Versus Host Disease (GVHD)1
2Unknown StatusTreatmentAllogeneic Transplantation / Haematological Malignancies1
2Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Diffuse Large Cell Lymphoma / Leukemias / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
2Unknown StatusTreatmentOcular Melanoma1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
3Active Not RecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood2
3CompletedTreatmentCancer, Ovarian1
3RecruitingTreatmentEwing's Sarcoma (ES)1
3Unknown StatusTreatmentMelanoma1
Not AvailableRecruitingNot AvailableAllogeneic Haematopoietic Stem Cell Transplantation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility17.0 mg/mLALOGPS
logP-1.5ALOGPS
logP-2.6ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)12.99ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area127.2 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity51.98 m3·mol-1ChemAxon
Polarizability24.93 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as organosulfonic acid esters. These are esters of sulfonic acid, which have the general structure RS(=O)2OR' (R,R' = organyl, not H).
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic sulfonic acids and derivatives
Sub Class
Organosulfonic acids and derivatives
Direct Parent
Organosulfonic acid esters
Alternative Parents
Sulfonic acid esters / Sulfonyls / Methanesulfonates / Secondary alcohols / 1,2-diols / Organic oxides / Hydrocarbon derivatives
Substituents
Organosulfonic acid ester / Sulfonic acid ester / Sulfonyl / Methanesulfonate / Secondary alcohol / 1,2-diol / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organosulfur compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
methanesulfonate ester (CHEBI:82557)

Drug created on October 20, 2016 14:39 / Updated on November 09, 2017 04:54